Urology
Volume 69, Issue 3 , Pages 526-531 , March 2007

Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse After Definitive Radical Retropubic Prostatectomy or Radiotherapy

  • Gopal K. Bajaj

      Affiliations

    • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • ,
  • Zhe Zhang

      Affiliations

    • Department of Oncology Biostatistics, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Elizabeth Garrett-Mayer

      Affiliations

    • Department of Oncology Biostatistics, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Renee Drew

      Affiliations

    • Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Victoria Sinibaldi

      Affiliations

    • Department of Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Roberto Pili

      Affiliations

    • Department of Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Samuel R. Denmeade

      Affiliations

    • Department of Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Michael A. Carducci

      Affiliations

    • Department of Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Mario A. Eisenberger

      Affiliations

    • Department of Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, Maryland
    • ,
  • Theodore L. DeWeese

      Affiliations

    • Department of Radiation Oncology, Johns Hopkins Hospital, Baltimore, Maryland
    • Corresponding Author InformationReprint requests: Theodore L. DeWeese, M.D., Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Hospital, 401 North Broadway, Suite 1440, Weinberg, Baltimore, MD 21231.

Received 31 March 2006 ,Accepted 11 December 2006.

References 

  1. American Cancer Society. Cancer facts and figures 2006. Atlanta, GA: American Cancer Society; 2006;
  2. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science. 1989;243:1564–1570
  3. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell. 1986;46:155–169
  4. Kelly JD, Haldeman BA, Grant FJ, et al. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem. 1991;266:8987–8992
  5. Escobedo JA, Barr PJ, Williams LT. Role of tyrosine kinase and membrane-spanning domains in signal transduction by the platelet-derived growth factor receptor. Mol Cell Biol. 1988;8:5126–5131
  6. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44:77–87
  7. Sitaras NM, Sariban E, Bravo M, et al. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res. 1988;48:1930–1935
  8. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol. 1994;7:549–554
  9. Vlahos CJ, Kriauciunas TD, Gleason PE, et al. Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells. J Cell Biochem. 1993;52:404–413
  10. Ko YJ, Small EJ, Kabbinavar F, et al. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001;7:800–805
  11. George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology. 2002;60(3 suppl 1):115–122
  12. Shawver LK, Schwartz DP, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res. 1997;3:1167–1177
  13. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283–1316
  14. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002;38(suppl 5):S52–S59
  15. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  16. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003;95:458–470
  17. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–145
  18. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  19. Kantarjian HM, Cortes JE, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979–1988
  20. Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:1212–1219
  21. Rao K, Goodin S, Levitt MJ, et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate. 2005;62:115–122
  22. Tiffany NM, Wersinger EM, Garzotto M, et al. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology. 2004;63:934–939
  23. Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004;22:3323–3329
  24. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48:201–206
  25. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol. 2005;23:5235–5246
  26. DiPaola RS, Chenven ES, Shih WJ, et al. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 2001;92:2065–2071
  27. Hofer MD, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia. 2004;6:503–512

PII: S0090-4295(06)02630-6

doi: 10.1016/j.urology.2006.12.006

Urology
Volume 69, Issue 3 , Pages 526-531 , March 2007

Article Tools

* Image Usage & Resolution